| Molecular formula | C101H152N28O22S2 |
|---|
| Molecular weight | 2174.6 g/mol |
|---|
| Registered trials | 9 |
|---|
| PubChem CID | 146675088 |
|---|
What MOTS-c Is
MOTS-c is a synthetic peptide modeled on a mitochondrial-derived signaling sequence, with the molecular formula C101H152N28O22S2 and a molecular weight of roughly 2174.6 daltons (PubChem CID 146675088). It has no FDA-approved label, no approved brand name, and is currently classified as an unapproved compound used only in research settings. No indications, dosing, or clinical use have been authorized by any regulatory agency.
Clinical Trial Activity
Nine registered trials reference MOTS-c, reflecting early-stage academic and clinical interest rather than an established evidence base. Sample studies include a deafness-gene screening cohort listed as active but not recruiting, a trial examining high-intensity physical exercise in people with dialyzed chronic kidney disease that is currently recruiting, and a study evaluating insulin sensitivity in adults with prediabetes and overweight or obesity that is also recruiting. These titles describe study design and target populations only and do not represent confirmed outcomes or approved uses.
FAQ
MOTS-c is a synthetic peptide based on a mitochondrial-derived sequence, identified in research databases by the molecular formula C101H152N28O22S2. It has no FDA-approved label or brand name and is used only in research contexts, not as a marketed drug.
No. MOTS-c is an unapproved research compound with no FDA-approved label, indications, or authorized medical use. It is not sold or prescribed as an approved drug in the United States.
Registered trials referencing MOTS-c include research on insulin sensitivity in adults with prediabetes and overweight or obesity, exercise effects in people with dialyzed chronic kidney disease, and a deafness-gene screening cohort. These are ongoing or completed study listings, not confirmed findings or approved uses.
No adverse event report data is currently available for MOTS-c, since it is not an approved drug tracked through standard post-market safety databases. Safety information for unapproved compounds used in research is limited to what individual studies report.
As of the most recent data pull, nine registered trials reference MOTS-c. Some of these are actively recruiting participants, while others are no longer recruiting or have reached other statuses.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-08-03